GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Ceftazidime / avibactam (Avycaz)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Avycaz

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

AVYCAZ - adult U.S. label renal table

Product / population
Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.
Renal measure
Cockcroft-Gault CrCl, mL/min.

Dosing / renal protocol and limits

Adult labeled cIAI, cUTI/pyelonephritis and HABP/VABP dosing uses total combination grams, all infused IV over 2 hours.

Cockcroft-Gault CrCl (mL/min)DoseInterval
>502.5 gEvery 8 hours
31-501.25 gEvery 8 hours
16-300.94 gEvery 12 hours
6-150.94 gEvery 24 hours
<=50.94 gEvery 48 hours

On HD days, administer after dialysis. For changing renal function, reassess clearance at least daily. Adult cIAI treatment also includes metronidazole. This label's 2-hour infusion differs from the UCSF 3-hour strategy; its <=5 band also resolves a boundary omitted by that institutional page. Pediatric dosing requires a separate age/eGFR table, not this adult table.

Source revision: Label revised April 2025; DailyMed updated 2025-04-30. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

AVYCAZ - adult U.S. label renal table

Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - AVYCAZ extended-infusion protocol

Adults; IV ceftazidime/avibactam combined dose; ID/antimicrobial-stewardship restricted.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Nebraska Medicine - AVYCAZ renal and HD/PD schedule

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Adult CrCl estimate mL/min; dialysis row is separate
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAVYCAZ - adult U.S. label renal tableUCSF - AVYCAZ extended-infusion protocolNebraska Medicine - AVYCAZ renal and HD/PD schedule
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Compare complete versions: U.S. labeling uses 2-hour infusions, while UCSF uses 3-hour extended infusions. Nebraska separately lists an HD/PD interval different from the label. Do not select a dose from one version and an interval from another.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd

Product and population scope

Adult Ceftazidime / avibactam (Avycaz). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-ceftazidime-avibactam · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

AVYCAZ - adult U.S. label renal table

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min.
Source date: Label revised April 2025; DailyMed updated 2025-04-30.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult labeled cIAI, cUTI/pyelonephritis and HABP/VABP dosing uses total combination grams, all infused IV over 2 hours.

Cockcroft-Gault CrCl (mL/min)DoseInterval
>502.5 gEvery 8 hours
31-501.25 gEvery 8 hours
16-300.94 gEvery 12 hours
6-150.94 gEvery 24 hours
<=50.94 gEvery 48 hours

On HD days, administer after dialysis. For changing renal function, reassess clearance at least daily. Adult cIAI treatment also includes metronidazole. This label's 2-hour infusion differs from the UCSF 3-hour strategy; its <=5 band also resolves a boundary omitted by that institutional page. Pediatric dosing requires a separate age/eGFR table, not this adult table.

RDM30-067-ceftazidime-avibactam-1 · Source locator: AVYCAZ - adult U.S. label renal table; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd
Retrieved
2026-09-05
DailyMed Set ID
d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd
Renal-function method
Cockcroft-Gault CrCl, mL/min.
Source date/version
Label revised April 2025; DailyMed updated 2025-04-30.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
8e0cfc7c9bfb8b271f6f38ce85822906b0fca728f426eace4a0a2931b60d894e
Separate professional-source layer

University and professional protocols

Professional

UCSF - AVYCAZ extended-infusion protocol

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; IV ceftazidime/avibactam combined dose; ID/antimicrobial-stewardship restricted.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

The columns omit exactly 5. All these institutional infusions last 3 hours; do not silently substitute the product-label infusion duration.

Combination amount - IV over 3 hours
CrCl, mL/minSource-specific dose / instruction
>502.5 g every 8 hours
31-501.25 g every 8 hours
16-300.94 g every 12 hours
6-150.94 g every 24 hours
<50.94 g every 48 hours
Dialysis guidance - separate source-specific schedules
Ceftazidime/avibactam - dialysis
Dialysis setting / indicationSource-specific schedule
IHD0.94 g initially, then each evening
IHD alternative - minimal residual function and less severe infection0.94 g every 48 hours in the evening
CVVHD2.5 g every 8 hours
Read the retained text before reformatting

Doses refer to the combined product and are infused IV over 3 hours. CrCl columns as published (>50 / 31-50 / 16-30 / 6-15 / <5 mL/min) correspond to 2.5 g every 8 hours / 1.25 g every 8 hours / 0.94 g every 12 hours / 0.94 g daily / 0.94 g every 48 hours.

The published columns omit exactly 5 mL/min; that boundary is not repaired by assumption.

IHD: 0.94 g initially, then each evening. For minimal residual kidney function and less severe infection, an alternative is 0.94 g every 48 hours in the evening. CVVHD: 2.5 g every 8 hours. All these institutional infusions last 3 hours; retain separately from product-label infusion instructions.

RDM30-006-ceftazidime-avibactam-1 · Source locator: UCSF - AVYCAZ extended-infusion protocol; renal/dosing sections and stated qualifiers

Source-specific limits

The website writes <5 rather than <=5. Exact-boundary ambiguity is retained.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ceftazidime-avibactam-avycaz
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
7f22beac10b55f90715c9060361449aeb7e77eafafd64a883f76716478d7edb7
Professional

Nebraska Medicine - AVYCAZ renal and HD/PD schedule

Open original reference

Open / share this exact local source

Nebraska Medicine / UNMC · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Adult CrCl estimate mL/min; dialysis row is separate
Source date: Retrieved PDF page 14; revision date not independently established
Retrieved: 2026-09-05

Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult baseline 2.5 g IV every 8 hours; all doses over 2 hours. CrCl 31-50: 1.25 g every 8 hours; 16-30: 0.94 g every 12 hours; 6-15: 0.94 g daily; <=5: 0.94 g every 48 hours. The separate HD/PD row uses 0.94 g daily with limited data, after dialysis on HD days. This dialysis interval differs from the U.S. label and is not silently reconciled.

RDM30-107-ceftazidime-avibactam-1 · Source locator: Nebraska Medicine - AVYCAZ renal and HD/PD schedule; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/dose-nm-anti-infective-renal-dosing-guidelines.pdf
Retrieved
2026-09-05
Renal-function method
Adult CrCl estimate mL/min; dialysis row is separate
Source date/version
Retrieved PDF page 14; revision date not independently established
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
7fa3914081ad57fb9ed1181cf3ef925cf7092f477ff2bec8701263ed3c7c686d

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
eb9fec33454f3a8ab6687f7fafe83e191d9276145ee0c09ee19b05a6ad5298d3
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report